Amyloid as a depot for the formulation of long-acting drugs

被引:182
作者
Maji, Samir K. [1 ]
Schubert, David [2 ]
Rivier, Catherine [3 ]
Lee, Soon [3 ]
Rivier, Jean E. [3 ]
Riek, Roland [1 ,4 ]
机构
[1] Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA
[2] Salk Inst Biol Studies, Cellular Neurobiol Lab, La Jolla, CA 92037 USA
[3] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA
[4] ETH, Phys Chem Lab, CH-8092 Zurich, Switzerland
关键词
X-RAY-DIFFRACTION; FIBRIL FORMATION; HORMONE ANTAGONISTS; ALZHEIMERS-DISEASE; BETA-SHEET; A-BETA; DELIVERY; PROTEIN; GONADOTROPIN; RELEASE;
D O I
10.1371/journal.pbio.0060017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Amyloids are highly organized protein aggregates that are associated with both neurodegenerative diseases such as Alzheimer disease and benign functions like skin pigmentation. Amyloids self-polymerize in a nucleation-dependent manner by recruiting their soluble protein/peptide counterpart and are stable against harsh physical, chemical, and biochemical conditions. These extraordinary properties make amyloids attractive for applications in nanotechnology. Here, we suggest the use of amyloids in the formulation of long-acting drugs. It is our rationale that amyloids have the properties required of a long-acting drug because they are stable depots that guarantee a controlled release of the active peptide drug from the amyloid termini. This concept is tested with a family of short-and long-acting analogs of gonadotropin-releasing hormone ( GnRH), and it is shown that amyloids thereof can act as a source for the sustained release of biologically active peptides.
引用
收藏
页码:240 / 252
页数:13
相关论文
共 60 条
[1]   Curli biogenesis and function [J].
Barnhart, Michelle M. ;
Chapman, Matthew R. .
ANNUAL REVIEW OF MICROBIOLOGY, 2006, 60 :131-147
[2]   HYDROGEN-PEROXIDE MEDIATES AMYLOID-BETA PROTEIN TOXICITY [J].
BEHL, C ;
DAVIS, JB ;
LESLEY, R ;
SCHUBERT, D .
CELL, 1994, 77 (06) :817-827
[3]   Diabetes care in childhood and adolescence [J].
Betts, PR ;
Jefferson, IG ;
Swift, PGF .
DIABETIC MEDICINE, 2002, 19 :61-65
[4]   Hybrid insulin cocrystals for controlled release delivery [J].
Brader, ML ;
Sukumar, M ;
Pekar, AH ;
McClellan, DS ;
Chance, RE ;
Flora, DB ;
Cox, AL ;
Irwin, L ;
Myers, SR .
NATURE BIOTECHNOLOGY, 2002, 20 (08) :800-804
[5]   Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix [J].
Broqua, P ;
Riviere, PJM ;
Conn, PM ;
Rivier, JE ;
Aubert, ML ;
Junien, JL .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (01) :95-102
[6]   PHYSICOCHEMICAL PROPERTIES OF A-75998, AN ANTAGONIST OF LUTEINIZING-HORMONE-RELEASING HORMONE [J].
CANNON, JB ;
KRILL, SL ;
PORTER, WR .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (08) :953-958
[7]   Designing conditions for in vitro formation of amyloid protofilaments and fibrils [J].
Chiti, F ;
Webster, P ;
Taddei, N ;
Clark, A ;
Stefani, M ;
Ramponi, G ;
Dobson, CM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3590-3594
[8]   Protein misfolding, functional amyloid, and human disease [J].
Chiti, Fabrizio ;
Dobson, Christopher M. .
ANNUAL REVIEW OF BIOCHEMISTRY, 2006, 75 :333-366
[9]   Agrin binds to β-amyloid (Aβ), accelerates Aβ fibril formation, and is localized to AB deposits in Alzheimer's disease brain [J].
Cotman, SL ;
Halfter, W ;
Cole, GJ .
MOLECULAR AND CELLULAR NEUROSCIENCE, 2000, 15 (02) :183-198
[10]   INSULIN AS AN AMYLOID-FIBRIL PROTEIN AT SITES OF REPEATED INSULIN INJECTIONS IN A DIABETIC PATIENT [J].
DISCHE, FE ;
WERNSTEDT, C ;
WESTERMARK, GT ;
WESTERMARK, P ;
PEPYS, MB ;
RENNIE, JA ;
GILBEY, SG ;
WATKINS, PJ .
DIABETOLOGIA, 1988, 31 (03) :158-161